CHRN
ChronoScale Corp
Next earnings Jul 27, 2026 · consensus $-0.06 EPS, $2.55M rev
Last earnings +13.0% on 2026-02-17
$22.23
▼ -1.24%$22.23▲ +671.88%
over 1Y
L $2.82EODHDH $25.82
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.2%
1W-13.4%
1M+49.8%
3M+119.0%
YTD+183.5%
1Y+671.9%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Cash-burning exoskeleton micro-cap with collapsing revenue, $1.2M cash against $11.8M annual burn — going-concern math doesn't work.
ChronoScale (operating as an exoskeleton maker — EksoNR, Ekso Indego, EVO) is in acute financial distress masquerading as a turnaround story. FY2025 revenue collapsed 29% to $12.8M — and crucially, the MD&A attributes this to a drop in Enterprise Health device volume in EMEA, the company's core revenue engine, only partially offset by Personal Health gains. The CMS reimbursement narrative for Ekso Indego Personal (approved April 2024 at ~$91,000) is the bull case, but two years in it has not arrested the top-line decline. Gross margin held at 53%, which is the only fundamental positive here.
Sources: SEC EDGAR (CIK 0001549084, latest 10-Q filed 2026-04-28) · EODHD · analysis by claude-code · as of 6/25/2026, 1:46:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.